Sam Brusco, Associate Editor01.02.23
Minerva Surgical, a company focused on treatment of abnormal uterine bleeding (AUB), has announced David Clapper, who has been president and CEO since 2011, will retire. The company appointed industry executive Todd Usen as its new president and CEO and is succeeding Clapper effective today.
Clapper entered into a consulting agreement to 12 months following his retirement to ensure a smooth leadership transition.
“On behalf of the Board, the management team, and Minerva Surgical’s employees, we want to thank Dave for his leadership and impact over the last eleven years, building a leading business in women’s health,” Ross Jaffe, MD, Minerva Surgical’s chairman told the press. “We appreciate Dave securing our latest financing as well as assisting in the search to find a strong successor, both of which ensure that Minerva Surgical is well-positioned going forward.”
“It’s been a great privilege to collaborate with our incredible team to serve Minerva Surgical’s stockholders, customers, and employees, and I am so proud of what we’ve accomplished together,” added Clapper. “I have served over eleven years as CEO, and I feel this is the right time for me to step aside and start a new chapter in my life. Minerva Surgical is in a great operational position and is led by an experienced management team. I have the utmost confidence in Todd to lead Minerva Surgical into the future and fulfill the mission to meet the uterine health needs of women.”
Usen for the last four years was CEO of Activ Surgical, a digital surgery company focused on advanced surgical imaging and artificial intelligence (AI). From 2015 to 2018, he was president of Olympus Corp. of the Americas’ medical systems group. Prior to that, he served in exec positions including president of United States Orthopedics, senior VP/GM of Joint Reconstruction and senior VP of Sports Medicine at Smith+Nephew, and VP sales and director of sales at Boston Scientific.
“I am honored to join Minerva Surgical and look forward to working with the entire organization to continue driving value for all stakeholders, but most importantly women all over the world who experience heavy bleeding, leading to unnecessary hysterectomies,” said Usen. “With the most convincing clinical data in the market, a strong commercial footprint and the recently announced financing, I believe that Minerva Surgical is poised to scale our growth and deliver best-in-class surgical solutions to better serve the compelling unmet needs in women’s health today.”
Clapper entered into a consulting agreement to 12 months following his retirement to ensure a smooth leadership transition.
“On behalf of the Board, the management team, and Minerva Surgical’s employees, we want to thank Dave for his leadership and impact over the last eleven years, building a leading business in women’s health,” Ross Jaffe, MD, Minerva Surgical’s chairman told the press. “We appreciate Dave securing our latest financing as well as assisting in the search to find a strong successor, both of which ensure that Minerva Surgical is well-positioned going forward.”
“It’s been a great privilege to collaborate with our incredible team to serve Minerva Surgical’s stockholders, customers, and employees, and I am so proud of what we’ve accomplished together,” added Clapper. “I have served over eleven years as CEO, and I feel this is the right time for me to step aside and start a new chapter in my life. Minerva Surgical is in a great operational position and is led by an experienced management team. I have the utmost confidence in Todd to lead Minerva Surgical into the future and fulfill the mission to meet the uterine health needs of women.”
Usen for the last four years was CEO of Activ Surgical, a digital surgery company focused on advanced surgical imaging and artificial intelligence (AI). From 2015 to 2018, he was president of Olympus Corp. of the Americas’ medical systems group. Prior to that, he served in exec positions including president of United States Orthopedics, senior VP/GM of Joint Reconstruction and senior VP of Sports Medicine at Smith+Nephew, and VP sales and director of sales at Boston Scientific.
“I am honored to join Minerva Surgical and look forward to working with the entire organization to continue driving value for all stakeholders, but most importantly women all over the world who experience heavy bleeding, leading to unnecessary hysterectomies,” said Usen. “With the most convincing clinical data in the market, a strong commercial footprint and the recently announced financing, I believe that Minerva Surgical is poised to scale our growth and deliver best-in-class surgical solutions to better serve the compelling unmet needs in women’s health today.”